Michael Ehlers is taking a new job in biotech, and it says something about where the industry's attention is heading.
According to Endpoints News, Ehlers has left his role as CEO of Ascidian Therapeutics — the exon editing company he co-founded — to lead research and development at Formation Bio, which Endpoints describes as an AI biotech.
Endpoints notes that it isn't often that biotech executives make this kind of move. Stepping away from the top job at a company you helped start, and one working on a cutting-edge genetic technology like exon editing, is not a routine career step. Doing so to run R&D at an AI-focused drug company suggests Ehlers sees momentum in applying artificial intelligence to the long, expensive process of discovering and developing new medicines.
The two companies sit at different frontiers of the field. Ascidian focuses on exon editing, an approach aimed at repairing or rewriting parts of RNA. Formation Bio's pitch, by contrast, centers on using AI to speed up drug development. Bringing in a scientist-founder with deep experience building a genetic-medicine company gives Formation Bio senior R&D leadership as it pursues that strategy.
The same Endpoints report also carried separate news that a co-founder of Black Diamond has died at 67.
Why it matters: A respected founder trading a genetic-medicine CEO seat to run R&D at an AI-driven drug company is a small but telling signal of how seriously the biotech industry is now taking artificial intelligence.